Companies › Novavax
Novavax: clinical trials, targets and expected readouts
1 active drug program in 1 registered trial: 1 Phase 4; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
Programs Drug Target Highest phase Conditions Next expected readout NVX-CoV2705 Omicron JN.1 subvariant SARS-CoV-2 recombinant spike protein vaccine adjuvanted with Matri
SARS-COV-2 Phase 4 COVID-19 –
Trials Registry id Drug Phase Conditions Area Expected readout NCT07086222 NVX-CoV2705 Phase 4 COVID-19 Infectious disease Oct 2026
From the company's SEC filings Cash and short-term investments of $622m on 2026-09-30; operating cash outflow about $268m a year; runway about 28 months at that burn, to Jan 2029
Press releases filed as 8-K in the last year:
Agreements filed with the SEC (item 1.01), last two years 2026-01-20 · licence with Pfizer Inc · Entry into Material Definitive Agreements. License Agreement On January 15, 2026, (the “Effective Date”), Nova 2025-10-22 · acquisition with AstraZeneca Pharmaceuticals · October 17, 2025, Novavax, Inc. (the “Company”) entered into an assignment of the Company’s 700 Quince Orchard 2025-08-27 · agreement · On August 27, 2025, Novavax, Inc. (the “Company”) consummated (the “Closing”) the previously announced private 2025-05-05 · licence with Takeda Pharmaceutical · On April 29, 2025, Novavax, Inc. (the “Company”) entered into a collaboration and exclusive license agreement, 2024-12-18 · agreement · On December 12, 2024, Novavax Inc. (the “Company”) entered into Amendment #5 (the “Amendment”) to the Advanced 2024-12-04 · acquisition · Asset Purchase Agreement On December 3, 2024, Novavax CZ a.s. (the “Seller” or “Novavax CZ”), a wholly owned s
Companies built like this Valneva Austria Chengdu CoenBiotech Biofabri Vedanta Biosciences Osivax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.
Built from ClinicalTrials.gov, CTIS, FDA, PubMed and OpenAlex, read every week; this page from the landscape of 2026-11-09. Phaseline reads registries; it is not investment or medical advice. Method and sources · Privacy · Contact